Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity
Sebastian Fuchs, José M. Martinez-Navío, Michael Piatak, et al.
PLoS Pathogens (2015) Vol. 11, Iss. 8, pp. e1005090-e1005090
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

Adeno-associated virus vector as a platform for gene therapy delivery
Dan Wang, Phillip W.L. Tai, Guangping Gao
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 5, pp. 358-378
Open Access | Times Cited: 1817
Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression
José M. Martinez-Navío, Sebastian Fuchs, Shara N. Pantry, et al.
Immunity (2019) Vol. 50, Iss. 3, pp. 567-575.e5
Open Access | Times Cited: 108
Nef Secretion into Extracellular Vesicles or Exosomes Is Conserved across Human and Simian Immunodeficiency Viruses
Ryan P. McNamara, Lindsey M. Costantini, Tereance A. Myers, et al.
mBio (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 94
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Joseph P. Casazza, Evan M. Cale, Sandeep Narpala, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1022-1030
Open Access | Times Cited: 59
Host Anti-antibody Responses Following Adeno-associated Virus–mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys
José M. Martinez-Navío, Sebastian Fuchs, Sònia Pedreño‐López, et al.
Molecular Therapy (2015) Vol. 24, Iss. 1, pp. 76-86
Open Access | Times Cited: 67
HIV antibodies for treatment of HIV infection
David M. Margolis, Richard A. Koup, Guido Ferrari
Immunological Reviews (2017) Vol. 275, Iss. 1, pp. 313-323
Open Access | Times Cited: 67
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
Ami Patel, Mamadou A. Bah, David B. Weiner
BioDrugs (2020) Vol. 34, Iss. 3, pp. 273-293
Open Access | Times Cited: 55
Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models
Ekram Ahmed Chowdhury, Guy Meno‐Tetang, Hsueh Yuan Chang, et al.
Advanced Drug Delivery Reviews (2021) Vol. 170, pp. 214-237
Closed Access | Times Cited: 54
Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
Sebastian Fuchs, Ronald C. Desrosiers
Molecular Therapy — Methods & Clinical Development (2016) Vol. 3, pp. 16068-16068
Open Access | Times Cited: 55
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Jacqueline M. Brady, David Baltimore, Alejandro B. Balazs
Immunological Reviews (2017) Vol. 275, Iss. 1, pp. 324-333
Open Access | Times Cited: 52
State of play and clinical prospects of antibody gene transfer
Kevin Hollevoet, Paul Declerck
Journal of Translational Medicine (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 52
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
Matthew R. Gardner, Ina Fetzer, Lisa Kattenhorn, et al.
Molecular Therapy (2019) Vol. 27, Iss. 3, pp. 650-660
Open Access | Times Cited: 52
Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge
Hugh C. Welles, Madeleine F. Jennewein, Rosemarie D. Mason, et al.
PLoS Pathogens (2018) Vol. 14, Iss. 12, pp. e1007395-e1007395
Open Access | Times Cited: 47
AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Matthew R. Gardner, Christoph H. Fellinger, Lisa Kattenhorn, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 502
Open Access | Times Cited: 47
Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, et al.
Antibodies (2023) Vol. 12, Iss. 3, pp. 46-46
Open Access | Times Cited: 15
Next-generation bNAbs for HIV-1 cure strategies
Angela I. Schriek, Yoann Aldon, Marit J. van Gils, et al.
Antiviral Research (2023) Vol. 222, pp. 105788-105788
Open Access | Times Cited: 13
Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
José M. Martinez-Navío, Sebastian Fuchs, Desiree E. Mendes, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 37
AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
Fiona T. van den Berg, Makoah N. Aminake, Stuart A. Ali, et al.
Molecular Therapy — Methods & Clinical Development (2019) Vol. 14, pp. 100-112
Open Access | Times Cited: 36
The potential of engineered antibodies for HIV-1 therapy and cure
Marloes Grobben, Richard AL Stuart, Marit J. van Gils
Current Opinion in Virology (2019) Vol. 38, pp. 70-80
Open Access | Times Cited: 36
Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
Wei Zhan, Manish Muhuri, Phillip W.L. Tai, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 28
High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
Matthew R. Gardner, Desiree E. Mendes, Cláudia P. Muniz, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 24, pp. 199-206
Open Access | Times Cited: 19
Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge
Michael W. Grunst, Hwi Min Gil, Andres G. Grandea, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 1, pp. e1011819-e1011819
Open Access | Times Cited: 4
Effective Reduction of Transgene‐Specific Immune Response With rAAV Vectors Co‐Expressing miRNA‐UL112‐5p or ERAP1 shRNA
Huang Xiao-ping, Xiao Wang, Yaqi Sun, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 2
Open Access
Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy
Vadim A. Klenchin, Natasha M. Clark, Nida K. Keles, et al.
Science Immunology (2025) Vol. 10, Iss. 104
Open Access
Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1
Allen Lin, Alejandro B. Balazs
Retrovirology (2018) Vol. 15, Iss. 1
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top